PTK/ZK Not Dead Yet; R&D Efforts May Shift To Subgroup, Novartis Says
Executive Summary
Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7
You may also be interested in...
Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee
Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based on an open-label study.
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy